Quantum Genesis AI Corp (OTC: QTZM), operating as Quantumzyme Corp., is a biotransformation company focused on developing engineered enzymes for use in active pharmaceutical ingredient (API) production and clean chemistry applications. The company applies quantum mechanics, molecular modelling, and enzyme engineering techniques across a five-phase process: enzyme discovery, lab validation of wild-type enzymes, enzyme engineering, engineered enzyme validation, and scale-up in partnership with end users. As of the 10-K filed November 13, 2025, Quantumzyme had engineered its first product and had not yet reported material revenues, operating with a stockholders' deficit as of July 31, 2025. The company intends to expand beyond API production into fragrance and flavors, sustainable materials, plastic degradation, and carbon capture applications. CEO and CFO Naveen Krishnarao Kulkarni received a salary of $90,000 in each of fiscal years 2024 and 2025 (years ended July 31). The filing characterizes the company as pre-revenue and high-risk, with ongoing reliance on external capital to fund operations.

Revenue model

No material revenue has been reported in the excerpts from the 10-K filed November 13, 2025. The intended revenue model involves selling or licensing engineered enzyme products and partnering with end users for scale-up, but no revenue figures are disclosed in the available filing excerpts.

Products and services

Engineered enzymes for active pharmaceutical ingredient (API) production, using quantum mechanics and molecular modelling. The company has disclosed completion of its first engineered enzyme product as of the filing date. Planned expansion into enzymes for fragrance and flavors, sustainable materials, plastic degradation, and carbon capture.

Customers and end markets

Pharmaceutical companies requiring API synthesis. Planned future end markets include fragrance and flavors, sustainable materials, biofuels, and environmental remediation. No specific customer names or concentration data are disclosed in the filing excerpts.

Value-chain role

Research and development of engineered enzyme catalysts supplied to chemical and pharmaceutical manufacturers as alternatives to traditional hazardous chemical synthesis processes. The company positions its enzymes as enabling lower cost, improved yield, reduced impurities, and reduced hazardous waste relative to conventional chemistry.

Geographic exposure

No geographic revenue breakdown is disclosed in the filing excerpts. The company is incorporated in the United States and files with the SEC.

Source: SEC 10-K, filed 2025-11-13

Industry: Industrial Organic Chemicals